Insights

Innovative Vaccine Platform Gylden's development of synthetic T cell-priming vaccines with advanced skin delivery technology positions it at the forefront of immunotherapy, providing opportunities to collaborate with organizations seeking cutting-edge infectious disease solutions.

Expanding Disease Focus With pipelines targeting Betacoronaviruses, dengue, influenza, bacterial infections, and therapeutics for migraine and cancer, Gylden offers multiple avenues for partners interested in diverse therapeutic areas across infectious diseases and chronic conditions.

Unique Transdermal Technology The company's proprietary microneedle patch and nanocluster delivery systems present a compelling value proposition for companies aiming to enhance vaccine logistics, improve patient compliance, and explore innovative administration methods.

Strategic Global Footprint Gylden's facilities in the UK and the US, complemented by an operating subsidiary, enable access to key markets and collaboration opportunities for partners across North America and Europe in biotech development and manufacturing.

Financial and Growth Potential With revenue estimates between 1 and 10 million dollars and a focus on rapid, broad-spectrum immunotherapies, Gylden offers a promising partner for investors and companies seeking growth in the biotech sector with innovative immunomodulation solutions.

Similar companies to Gylden Pharma

Gylden Pharma Tech Stack

Gylden Pharma uses 8 technology products and services including WordPress, oEmbed, Microsoft 365, and more. Explore Gylden Pharma's tech stack below.

  • WordPress
    Content Management System
  • oEmbed
    Dev Tools
  • Microsoft 365
    Email
  • JSON-LD
    Javascript Frameworks
  • Lightbox
    Javascript Libraries
  • Google Maps
    Maps
  • PHP
    Programming Languages
  • All in One SEO
    Search Engines

Media & News

Gylden Pharma's Email Address Formats

Gylden Pharma uses at least 2 format(s):
Gylden Pharma Email FormatsExamplePercentage
F.Last@emergexvaccines.comJ.Doe@emergexvaccines.com
60%
FL@emergexvaccines.comJD@emergexvaccines.com
38%
First.Last@emergexvaccines.comJohn.Doe@emergexvaccines.com
2%
F.Last@gyldenpharma.comJ.Doe@gyldenpharma.com
100%

Frequently Asked Questions

Where is Gylden Pharma's headquarters located?

Minus sign iconPlus sign icon
Gylden Pharma's main headquarters is located at 4 And 5 Dunmore Court Wootton Road St. Helen Without, England ox13 6bh United Kingdom. The company has employees across 2 continents, including EuropeNorth America.

What is Gylden Pharma's official website and social media links?

Minus sign iconPlus sign icon
Gylden Pharma's official website is gyldenpharma.com and has social profiles on LinkedInCrunchbase.

What is Gylden Pharma's SIC code NAICS code?

Minus sign iconPlus sign icon
Gylden Pharma's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Gylden Pharma have currently?

Minus sign iconPlus sign icon
As of February 2026, Gylden Pharma has approximately 35 employees across 2 continents, including EuropeNorth America. Key team members include Chief Technology Officer: L. R.Chief Scientific Officer: P. W.Vice President Clinical Operations: B. N.. Explore Gylden Pharma's employee directory with LeadIQ.

What industry does Gylden Pharma belong to?

Minus sign iconPlus sign icon
Gylden Pharma operates in the Biotechnology Research industry.

What technology does Gylden Pharma use?

Minus sign iconPlus sign icon
Gylden Pharma's tech stack includes WordPressoEmbedMicrosoft 365JSON-LDLightboxGoogle MapsPHPAll in One SEO.

What is Gylden Pharma's email format?

Minus sign iconPlus sign icon
Gylden Pharma's email format typically follows the pattern of F.Last@emergexvaccines.com. Find more Gylden Pharma email formats with LeadIQ.

When was Gylden Pharma founded?

Minus sign iconPlus sign icon
Gylden Pharma was founded in 2016.

Gylden Pharma

Biotechnology ResearchEngland, United Kingdom11-50 Employees

Gylden is a clinical-stage, privately held biotechnology company, headquartered in Abingdon, Oxfordshire, UK, with R&D and GMP manufacturing facilities in Milton Park, Oxfordshire, UK, an operating subsidiary in Doylestown, Pennsylvania, USA and a manufacturing facility in Fremont, CA, USA. The Company is pioneering the development of synthetic T cell-priming vaccines/immunotherapies designed to mimic the body’s natural cellular immune response to destroy and clear pathogen-infected cells to protect against some of the world’s most urgent health threats. The candidates are designed for delivery via novel skin immunisation into the epidermal layer, aiming to ease the burden and logistics of traditional preventative methods. 

Gylden’s first indications pursued are against infectious diseases: [i] including core candidates for Betacoronaviruses, Dengue Fever and Universal Influenza (including Pandemic Influenza), as well as [ii] intra-cellular bacterial infectious disease. Additional products include a patch-based therapeutic drug for migraine, and candidates for cardiometabolic disorders, as well as cancer immunotherapy. Gylden's product pipeline includes innovative candidates with potential for rapid, broad, and long-lasting prevention of viral infections as well as immunotherapies in other therapeutic categories. 

Gylden’s T cell-priming vaccines and immunotherapy candidates combine core technologies, [i] a proprietary MHC Class I “Ligandome Library" of experimentally-selected peptide antigens expressed on the surface of pathogen-infected cells, using Immunoproteomics and Multi-Omic technologies, [ii] a proprietary ultrasmall carbohydrate-passivated nanocluster carrier system designed to deliver synthetic peptides to the skin-resident immune system to elicit robust T cell responses, [iii] Microneedle Array Patch (MAP) transdermal delivery technology acquired from Zosano Pharma in 2022, and [iv] in-house GMP accredited nanomedicine manufacturing capabilities.

Section iconCompany Overview

Headquarters
4 And 5 Dunmore Court Wootton Road St. Helen Without, England ox13 6bh United Kingdom
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $1M$10M

    Gylden Pharma's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Gylden Pharma's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.